Key Points
- Gyre Therapeutics COO Weiguo Ye sold shares in two recent transactions, including 9,400 shares on May 20 at an average price of $6.15 for $57,810 and another 12,820 shares on May 21 for $78,843.
- After the May 20 sale, Ye still held 700,000 shares valued at about $4.3 million, and the transaction reduced his ownership by 1.33%.
- Gyre Therapeutics is trading near its 52-week low, and the stock has drawn mixed analyst sentiment with a current consensus rating of Hold and a consensus target price of $17.00.
Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) COO Weiguo Ye sold 9,400 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $6.15, for a total transaction of $57,810.00. Following the completion of the transaction, the chief operating officer directly owned 700,000 shares in the company, valued at $4,305,000. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Weiguo Ye also recently made the following trade(s):
- On Thursday, May 21st, Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00.
Gyre Therapeutics Price Performance
Shares of GYRE opened at $6.06 on Friday. The firm has a market capitalization of $587.99 million, a PE ratio of -67.33 and a beta of 2.03. The company's 50-day moving average is $7.24 and its 200-day moving average is $7.60. Gyre Therapeutics, Inc. has a fifty-two week low of $5.97 and a fifty-two week high of $11.61.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The company had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. Analysts predict that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
GYRE has been the topic of several research reports. Weiss Ratings downgraded shares of Gyre Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Monday, May 11th. Zacks Research downgraded shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Gyre Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $17.00.
View Our Latest Analysis on Gyre Therapeutics
Institutional Investors Weigh In On Gyre Therapeutics
Large investors have recently bought and sold shares of the company. Alliancebernstein L.P. grew its stake in Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company's stock worth $163,000 after buying an additional 1,900 shares in the last quarter. Barclays PLC grew its stake in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company's stock worth $131,000 after buying an additional 5,135 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Gyre Therapeutics during the third quarter worth about $111,000. Wells Fargo & Company MN grew its stake in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company's stock worth $91,000 after buying an additional 7,361 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after buying an additional 1,996 shares in the last quarter. 23.99% of the stock is currently owned by institutional investors and hedge funds.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
